Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02162 康諾亞生物
Keymed Biosciences
Listing Date2021/07/08
Listing Price53.300
 
Quote
  • 40.700 -2.300 (-5.349%)    Sink Below Listing Price
  • 15-min delayed, last update: 21/10/2021 17:59
Subscription Result
  • Subscription Rate
    429.97x
  • Guarantee One Lot Size
    70 lot
  • One Lot Success Rate
    6.5%
COMPANY PROFILE

Keymed Biosciences is a biotechnology company. It primarily focuses on the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas.

Its Core Product, CM310, is a highly potent antagonist antibody against interleukin-4 receptor -subunit (IL-4R), intended to treat various allergic diseases, such as moderate-to-severe atopic dermatitis (AD), moderate-to-severe eosinophilic asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP), and potentially chronic obstructive pulmonary disease (COPD).

The five clinical-stage drug candidates, each among the first three domestically-developed for its target or in its class to have obtained investigational new drug (IND) approval in China and/or the U.S. All of 33 patent applications were pending, including 16 patent applications in China, two patent applications in the U.S., seven patent applications under the Patent Cooperation Treaty and eight patent applications in other jurisdictions, relating to certain of drug candidates and technologies. Specifically, in relation to its Core Product, CM310.

The Group entered into an exclusive license agreement with CSPC Pharmaceutical Group Limited (01093) to develop and commercialize CM310 for the treatment of moderate and severe asthma, COPD and other respiratory diseases in China.

BASIC INFORMATION
MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Websitewww.keymedbio.com
Board Lot500
GLOBAL OFFERING
No. of Offer Shares58.26m shares
No. of International Offer Shares52.44m shares
No. of HK Offer Shares5.83m shares
Offer Price$50.50 - $53.30
Registrar & Transfer OfficeComputershare Hong Kong Investor Services
Stock Code2162
Sponsor(s)Morgan Stanley Asia Limited; China International Capital Corporation Hong Kong Securities Limited; Huatai Financial Holdings (Hong Kong) Limited
Underwriter(s)Morgan Stanley Asia Limited; China International Capital Corporation Hong Kong Securities Limited; Huatai Financial Holdings (Hong Kong) Limited; China Everbright Securities (HK) Limited
TIME TABLE
Application PeriodJun 25 (Fri) - Noon, Jun 30 (Wed)
Price Determination DateOn or Before 5pm, Jun 30 (Wed)
Result Announcement DateOn or Before Jul 7 (Wed)
Dispatch of Shares and Refund ChequesOn or Before Jul 7 (Wed)
Dealings in Shares commence onJul 8, 2021. (Thu)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
DIRECTORS
ExecutiveBo CHEN (Chairman), Changyu WANG, Gang XU
Non-ExecutiveQi CHEN, Dong LYU, Min Chuan WANG, Yilun LIU
Independent Non-ExecutiveXiao-Fan WANG, Yang KE, Cheuk Kin Stephen LAW, Linqing LIU
MAJOR SHAREHOLDERS
Director Bo CHEN and related parties35.35%
Hillhouse Capital10.39%
INCOME STATEMENT (RMB'000)
(Year ended Dec 31)
20202019
Pre-Taxed Profit(818,848)(167,512)--
Attributable Profit for the period(818,583)(167,512)--
OFFER STATISTICS (HK$)
Offer Price$50.50 - $53.30
Capitalization$13,685m - $14,444m
Unaudited pro forma adj NAV / share$14.26 - $14.97
USE OF PROCEEDS
Assuming the offer price being at the mid-point of $51.90, the net proceeds raised would be HK$2,863.8m, of which:
* $1,718.3m (60.0%) to R&D and commercialization of following Core Product ;
* $429.6m (15.0%) to preclinical evaluation and clinical development of our other pipeline drug candidates products ;
* $429.6m (15.0%) to payment of lease for new manufacturing and R&D facilities; and
* the balance of $286.4m (10.0%) as additional working capital.
RELATED STOCK COMPARISON
Code Name Nominal Change %Change
01801INNOVENT BIOdown76.900-0.400-0.517%
01877JUNSHI BIOdown41.050-0.800-1.912%
01952EVEREST MED-Bup44.0000.8501.970%
02096SIMCERE PHARMAup7.9500.0600.760%
02142HBM HOLDINGS-Bdown6.420-0.080-1.231%
02162KEYMED BIO-Bdown40.700-2.300-5.349%
02607SH PHARMAdown15.000-0.280-1.832%
02616CSTONE PHARMA-Bdown9.780-0.300-2.976%
06160BEIGENEdown224.200-3.800-1.667%
06998GENOR-Bdown11.020-0.140-1.254%
09688ZAI LAB-SBdown767.500-23.000-2.910%
09926AKESO-Bdown45.350-0.350-0.766%
09966ALPHAMAB-Bdown17.920-0.340-1.862%
15-min delayed, last updated: 21/10/2021 17:59
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
:
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.